CRISPR Therapeutics AG
CRSP
$43.37
-$2.16-4.74%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 5,828.74% | 16.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5,828.74% | 16.44% | |||
| Cost of Revenue | -11.96% | -29.47% | |||
| Gross Profit | 49.88% | 29.65% | |||
| SG&A Expenses | 4.05% | -10.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.44% | -27.04% | |||
| Operating Income | 41.35% | 27.19% | |||
| Income Before Tax | 56.96% | 32.01% | |||
| Income Tax Expenses | -20.09% | -31.93% | |||
| Earnings from Continuing Operations | 56.59% | 32.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 56.59% | 32.01% | |||
| EBIT | 41.35% | 27.19% | |||
| EBITDA | 43.31% | 28.02% | |||
| EPS Basic | 56.70% | 32.26% | |||
| Normalized Basic EPS | 57.09% | 32.26% | |||
| EPS Diluted | 56.77% | 32.21% | |||
| Normalized Diluted EPS | 57.09% | 32.26% | |||
| Average Basic Shares Outstanding | 0.27% | 0.37% | |||
| Average Diluted Shares Outstanding | 0.27% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
